GLS and breast carcinoma: FDX1 (P < 1E‐12), LIAS (P = 2.22E‐16), LIPT1 (P < 1E‐12), DLD (P < 5.46E‐09), DLAT (P = 3.14E‐02), PDHA1 (P = 1.15E‐07), MTF1 (P = 1.07E‐09), and GLS (P = 2.48E‐05) were downregulated in breast cancer, while PDHB (P = 5.04E‐07) and CDKN2A (P = 1.62E‐12) were upregulated (Fig. 2A).